Twenty-four mini-pool HCV RNA screening in a routine clinical virology laboratory setting: A six-year prospective study

Seme, Katja; Močilnik, Tina; Poljak, Mario

doi:10.1016/j.jviromet.2010.11.008

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pooling samples is one of the approaches used most widely for reducing the cost of screening. A good example is pooling samples for the detection of blood-borne viruses, which has been used successfully for a decade in transfusion or non-transfusion settings [Allain, 2000;Roth et al, 2002;Mine et al, 2003;Stramer et al, 2004;Seme et al, 2011]. It has been demonstrated recently that urine pools can be used for PCR-based screening of congenital CMV infection without influencing the sensitivity [Paixã o et al, 2005[Paixã o et al, , 2011.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Paradiž

Seme

Puklavec

et al. 2011

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Human cytomegalovirus (CMV) is the most frequent cause of congenital infection in humans. In the first prevalence study of congenital CMV infection in Eastern and Central Europe, all neonates born in a 22-month period in two Slovenian maternity units (total of 2,841 newborns) were screened prospectively for congenital CMV infection by a real-time polymerase chain reaction (PCR) in urine. In all newborns with positive screening results, plasma and dried blood spots (DBS) collected at birth were tested additionally for CMV DNA. Congenital CMV infection was confirmed by virus isolation from a urine sample collected within the first 2 weeks of life. Congenital CMV infection was identified in four out of 2,841 newborns tested (incidence 0.14%; 95% CI, 0.05-0.39%). In four newborns with confirmed congenital infection, the concentration of CMV DNA in urine ranged from 4.68 to 8.18 log(10) copies/ml, all four newborns had detectable CMV DNA in plasma taken at birth (1.26-3.34 log(10) copies/ml) and two out of four had detectable CMV DNA in DBS collected during newborn metabolic screening. None of the four newborns with confirmed congenital CMV infection was symptomatic. The study showed that the prevalence of congenital CMV infection at birth in Slovenia is among the lowest in the world and that CMV DNA PCR testing of urine is a suitable and affordable real-time screening strategy for congenital CMV infection. If it is performed in 24 mini-pools, the cost of screening is 1.4 €/newborn and the cost of detecting a single newborn with congenital CMV infection 1,000 €.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Paradiž

Seme

Puklavec

et al. 2011

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to anti-HCV, screening for HCV RNA in serum or plasma is now inevitable in transfusion settings, and HCV RNA testing should be part of the initial evaluation in cases of suspected acute hepatitis C, in immunocompromised patients, and in patients on hemodialysis (7). In some screening settings where a laboratory mainly serves high-risk populations such as intravenous drug users, 24-mini-pool HCV RNA screening of anti-HCV negative samples has been shown to be valuable and cost-effective (15,16).…”

Section: Introductionmentioning

confidence: 99%

Simplification of hepatitis C testing: a time to act

Poljak

2020

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

Self Cite

View full text Add to dashboard Cite

Twenty-four mini-pool HCV RNA screening in a routine clinical virology laboratory setting: A six-year prospective study

Cited by 2 publications

References 21 publications

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Simplification of hepatitis C testing: a time to act

Contact Info

Product

Resources

About